Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE
- 1 January 2007
- journal article
- clinical trial
- Published by Elsevier in Clinical Immunology
- Vol. 122 (1) , 62-74
- https://doi.org/10.1016/j.clim.2006.08.016
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Update on rituximabAnnals of the Rheumatic Diseases, 2005
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- T cells in the pathogenesis of systemic lupus erythematosusClinical Immunology, 2004
- Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeysTransplant Immunology, 2003
- Maintenance of Serological Memory by Polyclonal Activation of Human Memory B CellsScience, 2002
- Abnormal T cell signal transduction in systemic lupus erythematosusArthritis & Rheumatism, 2002
- B‐1 cells: the lineage question revisitedImmunological Reviews, 2000
- B‐cell subsets and the mature preimmune repertoire. Marginal zone and B1 B cells as part of a “natural immune memory”Immunological Reviews, 2000
- Analysis of the expression of CD5 by human B cells and correlation with functional activityCellular Immunology, 1992